Across all industries, the total number of companies on track to go public could make this week the most active for IPOs ...

Delve into what 2026 has to offer in the biotech industry. The market is showing signs it's picking up and the patent cliff ...

Shares Biotechnology ETF (IBB) is a BUY: large-cap biotech stability, M&A and AI catalysts, and 2026 upside. Read the full ...

11 companies raised US$4 billion in Hong Kong in the first three weeks of 2026, with hundreds more lining up to list, Bonnie ...

We all know someone waiting on a medical breakthrough. It could be a parent battling a chronic illness, a colleague pushing through long workdays while ...

Lower interest rates aided the biotech bounceback, as many companies in the sector rely on a big dose of debt. Their shares also rose as the number of patent cliffs for blockbuster drugs increased, ...

But deciding if it's a good buy takes a little more looking.

Local biotech entrepreneurs and investors are seeing signs that the four-year "biotech winter" is finally thawing, though ...

Uncover the systematic approach to biotech firm valuation using DCF. Equip yourself with the knowledge to gauge company potential accurately and confidently.

Michael Patten, chief strategy officer of Harbour BioMed, a global biotech group with Chinese roots that has a partnership ...

VanEck Biotech ETF gets a Hold rating as top holdings face low growth, patent cliffs, and rich valuation vs. peers. Click to read my latest analysis of BBH.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Strand Therapeutics today announced that Fierce Biotech has named it as one of 2022’s Fierce 15 biotechnology companies, designating it as one of the most promising ...